Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Mason Carrico - Stephens, Inc. Matt Sykes - Goldman Sachs Andrew Brackmann - William Blair Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper - Raymond James Operator Good day and thank you for standi ...

veracyte. 5/4/2023 1 Q1 2023 Business and Financial Presentation May 4, 2023 © Veracyte, Inc. All rights reserved. Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue for 2023 and other financial and operating results and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our tests and products, including our biopharma atlas, for ...

Our vision is to transform cancer care for patients all over the world. March 2023 3/7/20231 © Veracyte, Inc. All rights reserved. Forward-looking statements This presentation contains forwardlooking statements, including, but not limited to, our statements related to our expected total revenue for 2023, our expected growth rate in testing and product revenue in 2023, our 2023 nonGAAP gross margin, and our plans, objectives, expectations (financial and otherwise), our strategic growth driver, or intentions ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☐ OF 1934 For the transition period from to Commission File Number 001-36156 VERACYTE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-5455398 (State or Other Jurisdiction of (I.R. ...

veracyte. 2/22/2023 1 Q4 and Full-Year 2022 Business and Financial Presentation February 22, 2023 © Veracyte, Inc. All rights reserved. Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue for 2023 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our tests and products. Forward-looking statements can be identified by words su ...

Start Time: 16:30 January 1, 0000 5:29 PM ET Veracyte, Inc. (NASDAQ:VCYT) Q4 2022 Earnings Conference Call February 22, 2023, 16:30 PM ET Company Participants Marc Stapley - CEO Rebecca Chambers - EVP and CFO Tina Nova - President, U.S. CLIA Business Shayla Gorman - Director, IR Conference Call Participants Andrew Brackman - William Blair Dave Delahunt - Goldman Sachs Puneet Souda - SVB Securities Mason Carrico - Stephens, Inc Mike Matson - Needham & Company Yuko Oku - Morgan Stanley Andrew Cooper - Raymond ...

Veracyte, Inc. (NASDAQ:VCYT) Q3 2022 Earnings Conference Call November 2, 2022 4:30 AM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Executive Vice President and Chief Financial Officer Tina Nova - President, U.S. CLIA Business Conference Call Participants Jacob Johnson - Stephens Griffin Soriano - William Blair Mike Matson - Needham & Company Hugo Leo - Morgan Stanley David Hein - Goldman Sachs Operator Good day, and thank y ...

Q3 2022 Business and Financial Presentation November 2, 2022 11/2/2022 © Veracyte, Inc. All rights reserved. 1 Forward-looking statements This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue and other financial and operating results for 2022 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, LymphMark, Decipher Prostate, Percepta Nasal Sw ...

veracyte. Q2 2022 Business and Financial Presentation August 2, 2022 8/2/2022 © Veracyte, Inc. All rights reserved. 1 Forward-looking statements This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue and other financial and operating results for 2022 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, LymphMark, Decipher Prostate, Percepta N ...

Veracyte, Inc. (NASDAQ:VCYT) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Tina Nova - President of CLIA Business Giulia Kennedy - Global Chief Scientific Officer and Chief Medical Officer Conference Call Participants Brian Weinstein - William Blair Puneet Souda - SVB Securities Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Andrew Coope ...